Skip to main content
Are you a healthcare professional?Join GLP1Zoom for HCPs →
GLP1ZoomFind provider
ConditionICD-10: G47.33

Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a sleep disorder where breathing repeatedly stops and starts because the airway collapses during sleep. It affects an estimated 30 million US adults, contributes to cardiovascular disease, daytime fatigue, and reduced quality of life — and is closely linked to obesity, with weight loss often dramatically improving symptoms. The FDA approved Zepbound (tirzepatide) in December 2024 specifically for moderate-to-severe OSA in adults with obesity, making it the first GLP-1 with this on-label indication.

Key facts

  • •~30 million US adults have OSA; 80%+ are undiagnosed (American Academy of Sleep Medicine)
  • •OSA prevalence is 2-4x higher in adults with obesity (BMI ≥30)
  • •Zepbound (tirzepatide) FDA-approved Dec 2024 for moderate-severe OSA + obesity
  • •In the SURMOUNT-OSA trial, tirzepatide reduced apnea-hypopnea index (AHI) by ~25-29 events/hour
  • •Weight loss of 10% can reduce OSA severity by 30-50% even without medication
  • •OSA increases risk of stroke, heart attack, atrial fibrillation, and type 2 diabetes

Why GLP-1 medications

OSA pathophysiology is driven significantly by excess soft tissue в upper airway and around the pharynx — both reduced by weight loss. GLP-1 medications produce 15-22% body-weight reduction, which directly decompresses the airway and reduces apnea events. The SURMOUNT-OSA trials (published 2024 NEJM) showed tirzepatide reduced AHI by ~25-29 events/hour at 52 weeks, with 43% of patients reaching the threshold for OSA resolution. Beyond the direct airway effect, GLP-1 also improves the metabolic profile (insulin resistance, inflammation) that worsens OSA outcomes.

Common symptoms

  • Loud, chronic snoring (often noted by a bed partner)
  • Gasping or choking awakenings during sleep
  • Witnessed pauses in breathing during sleep
  • Excessive daytime sleepiness despite adequate sleep duration
  • Morning headache, dry mouth, or sore throat
  • Difficulty concentrating, irritability, or mood changes
  • Nocturia (waking multiple times to urinate)
  • High blood pressure, particularly if difficult to control

How obstructive sleep apnea is diagnosed

Diagnosis requires an overnight sleep study (polysomnography in a sleep lab, or home sleep apnea test for selected patients). The Apnea-Hypopnea Index (AHI) — number of breathing interruptions per hour — categorizes severity: mild (5-14), moderate (15-29), severe (≥30). The STOP-BANG questionnaire is a common screening tool used in primary care to identify candidates for sleep testing. Untreated OSA is associated with substantially increased cardiovascular risk.

Treatment options

CPAP / BiPAP (gold standard)

Continuous Positive Airway Pressure delivered via mask during sleep keeps airway open. Highly effective when used; adherence is the main limitation (many patients can't tolerate the mask long-term).

GLP-1 medications (newer option)

Zepbound FDA-approved for moderate-severe OSA + obesity (Dec 2024). Reduces AHI through weight loss + direct airway effects. Now insurance-covered for this indication in many plans.

Oral appliances

Dental mandibular advancement devices reposition the jaw to keep airway open. Best for mild-moderate OSA or CPAP-intolerant patients.

Surgery

Uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement, or hypoglossal nerve stimulator (Inspire). Reserved for select anatomical cases.

Bariatric surgery

For severe obesity (BMI ≥35), bariatric surgery often resolves OSA entirely along with weight loss. Pre- and post-op sleep studies typically required.

Positional therapy

Side-sleeping devices for patients whose OSA is positional (worse when supine). Adjunct, not standalone treatment.

Lifestyle & self-care

  • Weight loss — even 5-10% body weight reduction substantially improves AHI
  • Avoid alcohol within 3 hours of bedtime — alcohol relaxes airway muscles, worsens OSA
  • Sleep on side (not back) — supine sleep increases airway collapse
  • Treat nasal congestion — chronic congestion worsens OSA
  • Maintain regular sleep schedule — sleep deprivation worsens OSA severity
  • Stop smoking — increases upper airway inflammation and apnea events

When to see a doctor

Make an appointment if you have:

  • →Loud snoring noticed by a bed partner, especially с witnessed apneas
  • →Excessive daytime sleepiness affecting work, driving, or quality of life
  • →High blood pressure that's difficult to control
  • →Morning headaches and dry mouth on waking
  • →BMI ≥30 with sleep complaints (much higher OSA risk)
  • →Heart disease, atrial fibrillation, or stroke history (OSA screening recommended)

Medications for Obstructive Sleep Apnea

Compounded Tirzepatide

tirzepatide (compounded)

From $149/mo

Zepbound

tirzepatide

From $349/mo

Mounjaro

tirzepatide

From $1023/mo

Wegovy

semaglutide

From $1349/mo

Not sure which medication is right for you?

Take our 60-second quiz and get a personalized match.

Take the quiz

Sources

Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.